Tumor-specific immunotherapy based on dominant models of natural tolerance

Medical Hypotheses

Volumn 54, Issue 4, 2000, Pages 531-536

  Montero, E ^a   Amador, J F ^a   Perez R ^a   Lage, A ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN;

AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CELL GROWTH; CELL PROLIFERATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LYMPHOCYTE COUNT; LYMPHOID CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 0034022716     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1999.0892     Document Type: Article

References (57)

1. Burnet F. M. The concept of immunological surveillance. Prog Exp Tumor Res. 13:1970;1-27.
2. Herberman R. B. Tumor immunology. JAMA. 268(20):1992;2935-2939.
3. Boon T., Cerottini J. C., Van-den-Eynde B., van-der-Bruggen P., Van-Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 12:1994;337-365.
4. Livingston P. O. Active specific immunotherapy in the treatment of patients with cancer. Oettgen H. F. Immunology and Allergy Clinics of North America. Human Cancer Immunology II, 1991;401-423 W.B Saunders, London.
5. Mitchell M. S., Kan-Mitchell J., Kempf R. A., Harel W., Shau H. Y., Lind S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 48(20):1988;5883-5893.
6. Robbins P. F., Kawakami Y. Human tumor antigens recognized by T cells. Curr Opin Immunol. 8(5):1996;628-636.
7. Houghton A. N., Eisinger M., Albino A. P., Cairncross J. C., Old L. J. Surface antigens of melanocyte differentiation and melanoma subsets. J Exp Med. 156(6):1982;1755-1766.
8. Kawakami Y., Eliyahu S., Delgado C. H. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA. 91(9):1994;3515-3519.
9. Boon T., van-der-Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med. 183(3):1996;725-729.
10. Canevari S., Pupa S. M., Menard S. 1975-1995 revised anti-cancer serological response: biological significance and clinical implications. Ann Oncol. 7(3):1996;227-232.
11. Wick M., Dubey P., Koeppen H. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med. 186(2):1997;229-238.
12. Speiser D. E., Miranda R., Zakarian A. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med. 186(5):1997;645-653.
13. Houghton A. N. Cancer antigens: immune recognition of self and altered self. J Exp Med. 180(1):1994;1-4.
14. Moudgil K. D., Sercarz E. E. Can antitumor immune responses discriminate between self and nonself? Immunol Today. 15(8):1994;353-355.
15. Naftzger C., Takechi Y., Kohda H., Hara I., Vijayasaradhi S., Houghton A. N. Immune response to a differentiation antigen induced by altered antigen: A study of tumor rejection and autoimmunity. Proc Natl Acad Sci USA. 93:1996;14809-14814.
16. Hara I., Nguyen H., Takechi Y., Gansbacher B., Chapman P. B., Houghton A. N. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. Int J Cancer. 61(2):1995;253-260.
17. Gilboa E. Immunotherapy of cancer with genetically modified tumor vaccines. Semin Oncol. 23(1):1996;101-107.
18. Kim C. J., Prevette T., Cormier J. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. J Immunother. 20(4):1997;276-286.
19. Restifo N. P. The new vaccines: building viruses that elicit antitumor immunity. Curr Opin Immunol. 8(5):1996;658-663.
20. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 12:1994;991-1045.
21. Marchand M., Weynants P., Rankin E. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer. 63(6):1995;883-885.
22. Sensi M., Farina C., Maccalli C. Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. J Clin Invest. 99(4):1997;710-717.
23. Parmiani G., Colombo M. P. Somatic gene therapy of human melanoma: preclinical studies and early clinical trials. Melanoma Res. 5(5):1995;295-301.
24. Mitchell M. S. Active specific immunotherapy of melanoma. Br Med Bull. 51(3):1995;631-646.
25. Nabel G. J., Yang Z. Y., Nabel E. G. Direct gene transfer for treatment of human cancer. Ann N Y Acad Sci. 772:1995;227-231.
26. Burnet F. M. A modification of Jerne's theory of antibody production using the concept of clonal selection. The Australian J Sci. 20:1957;67-69.
27. Lederberg J. Genes and antibodies-do antigens bear instruction for antibody specificity or do they select cell lines that arise by mutation? Science. 129:1959;1649-1653.
28. Ramsdell F., Lantz T., Fowlkes B. J. A nondeletional mechanism of thymic self tolerance. Science. 246:1989;1038-1041.
29. Roberts J. L., Sharrow S. O., Singer A. Clonal deletion and clonal anergy in the thymus induced by cellular elements with different radiation sensitivities. J Exp Med. 171(3):1990;935-940.
30. Coutinho A. Beyond clonal selection and network. Immunol Rev. 110:1989;63-87.
31. Lafaille J. J., Nagashima K., Katsuki M., Tonegawa S. High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice. Cell. 78(3):1994;399-408.
32. Gleeson P. A., Toh B. H., van-Driel I. R. Organ-specific autoimmunity induced by lymphopenia. Immunol Rev. 149:1996;97-125.
33. Le-Douarin N., Corbel C., Bandeira A. Evidence for a thymus-dependent form of tolerance that is not based on elimination or anergy of reactive T cells. Immunol Rev. 149:1996;35-53.
34. Saoudi A., Seddon B., Heath V., Fowell D., Mason D. The physiological role of regulatory T cells in the prevention of autoimmunity: the function of the thymus in the generation of the regulatory T cell subset. Immunol Rev. 149:1996;195-216.
35. Modigliani Y., Bandeira A., Coutinho A. A model for developmentally acquired thymus-dependent tolerance to central and peripheral antigens. Immunol Rev. 149:1996;155-174.
36. Barrett S. P., Toh B. H., Alderuccio F., van-Driel I. R., Gleeson P. A. Organ-specific autoimmunity induced by adult thymectomy and cyclophosphamide-induced lymphopenia. Eur J Immunol. 25(1):1995;238-244.
37. Fowell D., Mason D. Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subsets that inhibits this autoimmune potential. J Exp Med. 177(3):1993;627-636.
38. Penhale W. J., Farmer A., Mckenna R. P., Irvine W. J. Spontaneous thyroiditis in thymectomized and irradiated wistar rats. Clin Exp Immunol. 15(2):1973;225-236.
39. Sakaguchi S., Sakaguchi N. Organ specific autoimmune disease induced in mice by elimination of T cell subsets V. Neonatal administration of cyclosporin A causes autoimmune disease. J Immunol. 142:1989;471-480.
40. Sakaguchi N., Miyai K., Sakaguchi S. Ionizing radiation and autoimmunity. Induction of autoimmune disease in mice by high dose fractionated total lymphoid irradiation and its prevention by inoculating normal T cells. J Immunol. 152(5):1994;2586-2595.
41. Cohen I. R. Regulation of autoimmune disease: physiological and therapeutic. Immunol Rev. 94:1986;5-21.
42. Barrett S. P., van-Driel I. R., Tan S. S., Alderuccio F., Toh B. H., Gleeson P. A. Expression of a gastric autoantigen in pancreatic islets results in non-destructive insulitis after neonatal thymectomy. Eur J Immunol. 25(9):1995;2686-2694.
43. Freitas A. A., Rocha B. B. Lymphocyte population kinetics: a cellular competition model. Coutinho A., Kazatchkine M. D. Autoimmunity. Physiology and Disease. 1994;143-160 John Wiley & Sons Lts, New York.
44. Martinelli T. M., van-Driel I. R., Alderuccio F., Gleeson P. A., Toh B. H. Analysis of mononuclear cell infiltrate and cytokine production in murine autoimmune gastritis. Gastroenterology. 110(6):1996;1791-1802.
45. Taguchi O., Nishizuka Y. Autoimmune oophoritis in thymectomized mice: T cell requirement in adoptive cell transfer. Clin Exp Immunol. 42(2):1980;324-331.
46. Zinkernagel R. M., Ehl S., Aichele P., Oehen S., Kündig T., Hengartner H. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev. 156:1997;199-209.
47. Longenecker B. M., MacLean G. Prospects for Mucin Epitopes in Cancer Vaccines. The Immunologist. 1(3):1993;89-93.
48. Schreiber H., William E. P. Tumor Immunology. Fundamental Immunology. 1993;. p. 1143-1178.
49. Bartlett G. L. The effect of host immunity on the antigenic strength of primary tumors. J Natl Cancer Inst. 49:1972;493-504.
50. Old L. J., Boyse E. A., Clarke D. A., Carswell E. A. Antigenic properties of chemically-induced tumors. Ann NY Acad Sci. 101:1962;80-106.
51. Modigliani Y., Coutinho A., Pereira P. Establishment of tissue-specific tolerance is driven by regulatory T cells selected by thymic epithelium. Eur J Immunol. 26(8):1996;1807-1815.
52. Silvestrini R., Daidone M. G., Luisi A., Mastore M., Leutner M., Salvadori B. Cell proliferation in 3,800 node-negative breast cancers: consistency over time of biological and clinical information provided by 3H-thymidine labelling index. Int J Cancer. 74(1):1997;122-127.
53. Egan A. F., Chappel J. A., Burghaus P. A. Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum. Infect Immun. 63(2):1995;456-466.
54. Mombaerts P., Iacomini J., Johnson R. S., Herrup K., Tonegawa S., Papaioannou V. E. RAG-1-deficient mice have no mature B and T lymphocytes. Cell. 68(5):1992;869-877.
55. Suri-Payer E., Amar A. Z., Thornton A. M., Shevach E. M. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol. 160(3):1998;1212-1218.
56. Naughton G. K. ., Eisinger M., Bystryn J. C. Antibodies to normal human melanocytes in vitiligo. J Exp Med. 158(1):1983;246-251.
57. Song Y. H., Connor E., Li Y., Zorovich B., Balducci P., Maclaren N. The role of tyrosinase in autoimmune vitiligo. Lancet. 344(8929):1994;1049-1052.